Switch as maintenance to elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate: week 48 results in a clinical cohort

Perrier Marine; Charpentier Charlotte; Peytavin Gilles; Le Minh; Blondel Louis; Visseaux Benoit; Joly Veronique; Pinto Adriana; Matheron Sophie; Yazdanpanah Yazdan; Descamps Diane; Landman Roland

首页> 外文期刊>The Journal of Antimicrobial Chemotherapy >Switch as maintenance to elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate: week 48 results in a clinical cohort

【24h】

Switch as maintenance to elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate: week 48 results in a clinical cohort

机译：作为维护作为埃尔维斯格拉维尔/钴/胞质公共/替诺维尔富马霉素：第48周导致临床队列

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Objectives: To assess, in a clinical cohort, the efficacy of switching current ART in virologically suppressed patients to elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate as a single-tablet regimen (STR) using the PCR signal of the plasma viral load (pVL) assay and determination of plasma drug concentration (C-24).

机译：目标：在临床队列中评估，使用血浆病毒载量的PCR信号（PVL ）测定和测定血浆药物浓度（C-24）。

著录项

来源
《The Journal of Antimicrobial Chemotherapy》 |2017年第6期|共7页
作者
Perrier Marine; Charpentier Charlotte; Peytavin Gilles; Le Minh; Blondel Louis; Visseaux Benoit; Joly Veronique; Pinto Adriana; Matheron Sophie; Yazdanpanah Yazdan; Descamps Diane; Landman Roland;
展开▼
作者单位

Univ Paris Diderot Sorbonne Paris Cite IAME UMR 1137 F-75018 Paris France;

Univ Paris Diderot Sorbonne Paris Cite IAME UMR 1137 F-75018 Paris France;

Univ Paris Diderot Sorbonne Paris Cite IAME UMR 1137 F-75018 Paris France;

Univ Paris Diderot Sorbonne Paris Cite IAME UMR 1137 F-75018 Paris France;

Hop Bichat Claude Bernard AP HP Lab Pharmacol F-75018 Paris France;

Univ Paris Diderot Sorbonne Paris Cite IAME UMR 1137 F-75018 Paris France;

Univ Paris Diderot Sorbonne Paris Cite IAME UMR 1137 F-75018 Paris France;

Hop Bichat Claude Bernard AP HP Serv Malad Infect &

Trop F-75018 Paris France;

Univ Paris Diderot Sorbonne Paris Cite IAME UMR 1137 F-75018 Paris France;

Univ Paris Diderot Sorbonne Paris Cite IAME UMR 1137 F-75018 Paris France;

Univ Paris Diderot Sorbonne Paris Cite IAME UMR 1137 F-75018 Paris France;

Univ Paris Diderot Sorbonne Paris Cite IAME UMR 1137 F-75018 Paris France;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类治疗学;
关键词

相似文献

外文文献
中文文献
专利

1. Switching from twice-daily raltegravir plus tenofovir disoproxil fumarate/emtricitabine to once-daily elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate in virologically suppressed, HIV-1-infected subjects: 48 weeks data. [J] . A Mills, G Crofoot, R Ortiz, HIV clinical trials . 2014,第2期

机译：在经病毒学抑制，HIV-1感染的受试者中，从每日两次raltegravir联合替诺福韦富马酸替莫索尔/恩曲他滨改为每日一次Elvitegravir / cobicistat / emtricitabine /替诺福韦富马酸替索莫韦被艾滋病毒1感染的受试者：48周数据。
2. Infrequent development of drug resistance in HIV-1-infected treatment-naive subjects after 96 weeks of treatment with elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide or elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate [J] . Margot Nicolas, Cox Stephanie, Das Moupali, Antiviral therapy . 2017,第5期

机译：在用ElviteGravir / Cobicistat / Emtricistabine / Tenofovir Alafenaine或ElviteGravir / Cobicistat / Emtrickavir / Emtrickavir / Emtricicabine / Tenofovir Disocroxil umarate后，难以在96周的治疗后抗毒性抗药性治疗 - 幼稚科目
3. A randomized double-blind comparison of coformulated elvitegravir/ cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: Analysis of week 96 results [J] . ZolopaA., SaxP.E., DejesusE., JAIDS: Journal of acquired immune deficiency syndromes . 2013,第1期

机译：联合配制的依维格韦/ cobicistat /恩曲他滨/替诺福韦富马酸替诺福韦与依法韦仑/恩曲他滨/替诺福韦富马酸替莫韦特在HIV-1感染初始治疗中的随机双盲比较：分析第96周的结果
4. Modeling and simulation for dynamics of tenofovir disoproxil fumarate anti-HBV infection therapy [C] . Xiao Chen, Jianlong Qiu, Weiqi Qin, Chinese Automation Congress . 2017

机译：替诺福韦富马酸替诺福韦抗乙肝病毒感染治疗动力学建模与仿真
5. Week 48 Results of EMERALD: A Phase 3 Randomized Non-inferiority Study Evaluating the Efficacy and Safety of Switching from Boosted-protease Inhibitors (bPI) Plus Emtricitabine (FTC)/Tenofovir Disoproxil Fumarate (TDF) Regimens to the Once Daily (QD) Single-tablet Regimen (STR) of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) in Virologically Suppressed HIV-1-infected Adults [O] . Chloe Orkin, Jean-Michel Molina, Joel Gallant, 2017

机译：EMERALD的第48周结果：第3阶段的非劣效性研究评估了从加强蛋白酶抑制剂（bPI）加恩曲他滨（FTC）/替诺福韦富马酸替诺福韦酯（TDF）转换为每日一次（QD）的功效和安全性）在病毒学上被抑制感染了HIV-1的成年人中Darunavir / Cobicistat / Emtricitabine / Tenofovir Alafenamide（D / C / F / TAF）的单片治疗方案（STR）
6. Switch as maintenance to elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate: week 48 results in a clinical cohort [O] . Marine Perrier, Charlotte Charpentier, Gilles Peytavin, 2017

机译：作为维护作为埃尔维特格拉维尔/ Cobicistat / Emtricisabine / Tenofovir Disoproxil富马特：第48周导致临床队列

Switch as maintenance to elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate: week 48 results in a clinical cohort

摘要

著录项

相似文献

相关主题

期刊订阅